Eyepoint Vision Drug Fails Phase 3 Trial as Competitor Stock Climbs

By Ed Silverman · STAT News · 2026-08-18

According to reporting from STAT News, Eyepoint Pharmaceuticals announced that its experimental therapy for age-related blindness failed to hit its primary goal in a late-stage clinical study. Patients receiving the drug, Duravyu, were unable to maintain their vision with fewer i

According to reporting from STAT News, Eyepoint Pharmaceuticals announced that its experimental therapy for age-related blindness failed to hit its primary goal in a late-stage clinical study. Patients receiving the drug, Duravyu, were unable to maintain their vision with fewer i